New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Candel Therapeutics

Contributing Author

Recent Articles by Candel Therapeutics

Oct-03	Candel Therapeutics to Present at the SITC 2025 Annual Meeting CADL GlobeNewswire
Sep-29	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 CADL GlobeNewswire
Sep-17	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 CADL GlobeNewswire
Sep-02	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board CADL GlobeNewswire
Aug-28	Candel Therapeutics to Participate in Upcoming Investor Conferences in September CADL GlobeNewswire
Aug-14	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights CADL GlobeNewswire
Jul-30	Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference CADL GlobeNewswire
Jul-24	Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer CADL GlobeNewswire
Jul-09	Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution CADL GlobeNewswire
Jun-24	Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock CADL GlobeNewswire
Jun-23	Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer CADL GlobeNewswire
Jun-06	Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors CADL GlobeNewswire
May-28	Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer CADL GlobeNewswire
May-27	Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation CADL GlobeNewswire
May-22	Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 CADL GlobeNewswire
May-13	Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights CADL GlobeNewswire
May-06	Candel Therapeutics to Present at Upcoming Investor Conferences CADL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.